Extract
The major cause of lung damage in cystic fibrosis (CF) is infection with bacterial pathogens, the most prevalent of which is Pseudomonas aeruginosa (Pa), chronically infecting ∼60% patients by adolescence/adulthood (www.cysticfibrosis.org.uk/news/registry-report-2017). Pa may be successfully eradicated, but frequently recurs and establishes biofilms resistant to antibiotics/host defences [1]. Chronic Pa is closely linked with pulmonary exacerbation frequency, faster lung function decline and earlier mortality [2]. The huge antibiotic burden imposed upon patients and the resulting bacterial resistance, allergies and toxicities compound the detrimental impact of the infection itself. Chronic Pa should be avoided if at all possible; early detection and rapid treatment may be crucial in achieving this.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Davies reports other from Algipharma AS, other from Bayer AG, other from Boehringer Ingelheim Pharma GmbH & Co. KG, other from Galapagos NV, other from ImevaX GmbH, other from Nivalis Therapeutics, Inc., other from ProQR Therapeutics III B.V., other from Proteostasis Therapeutics, INC., other from Raptor Pharmaceuticals, Inc, other from Vertex Pharmaceuticals (Europe) Limited, other from Enterprise, other from Novartis, other from Pulmocide, other from Flatley, other from Nivalis Therapeutics Inc., grants from CF Trust, other from Teva, outside the submitted work.
Conflict of interest: Dr. Alton has nothing to disclose.
Conflict of interest: Dr. Simbo has nothing to disclose.
Conflict of interest: Mr. Murphy has nothing to disclose.
Conflict of interest: Dr. Seth has nothing to disclose.
Conflict of interest: Dr. Williams has nothing to disclose.
Conflict of interest: Mark Somerville has nothing to disclose.
Conflict of interest: Dr. Jolly has nothing to disclose.
Conflict of interest: Dr. Morant has nothing to disclose.
Conflict of interest: Dr. Guest has nothing to disclose.
- Copyright ©ERS 2019
INDIVIDUALS
Log in using your username and password
LIBRARY USERS
Log in through your institution
Purchase access
CONTACT US
If you have any questions about the ERS publications website, please contact journals@ersnet.org
